We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.6%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$126M
Cap. Flow
+$65.1M
Cap. Flow %
3.43%
Top 10 Hldgs %
54.31%
Holding
63
New
4
Increased
4
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$17.3M
2
ITOS
iTeos Therapeutics
ITOS
+$16.4M
3
SYRE icon
Spyre Therapeutics
SYRE
+$15.1M
4
CGEM icon
Cullinan Oncology
CGEM
+$14M
5
REPL icon
Replimune Group
REPL
+$10.7M

Top Sells

Rank Stock Value
1
VKTX icon
Viking Therapeutics
VKTX
+$24.6M
2
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$39.9B
$166M 8.75%
4,279,464
– –
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$129M 6.79%
3,421,541
– –
CYTK icon
3
Cytokinetics
CYTK
$10.5B
$114M 5.99%
2,100,000
– –
MRUS
4
DELISTED
Merus
MRUS
$112M 5.92%
1,900,000
– –
TYRA icon
5
Tyra Biosciences
TYRA
$1.9B
$103M 5.43%
6,448,359
– –
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.57B
$103M 5.41%
650,000
– –
NUVL
7
DELISTED
Nuvalent
NUVL
$85M 4.48%
1,120,192
– –
IDYA icon
8
IDEAYA Biosciences
IDYA
$3.42B
$77.3M 4.07%
2,202,812
– –
ONC
9
BeOne Medicines Ltd
ONC
$32.8B
$71.3M 3.76%
500,000
– –
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$70.6M 3.72%
1,727,388
– –
TNGX icon
11
Tango Therapeutics
TNGX
$4.43B
$70.3M 3.7%
8,198,642
– –
APLS
12
DELISTED
Apellis Pharmaceuticals
APLS
$66.2M 3.49%
1,726,000
– –
ITOS
13
DELISTED
iTeos Therapeutics
ITOS
$43.7M 2.3%
2,946,915
+1,142,857
+63% +$16.4M
ARGX icon
14
argenx
ARGX
$53.4B
$43M 2.26%
100,000
– –
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$39.3M 2.07%
1,676,733
– –
NKTX icon
16
Nkarta
NKTX
$150M
$33.1M 1.75%
5,607,350
– –
ANAB icon
17
AnaptysBio
ANAB
$1.58B
$32.6M 1.72%
1,300,000
– –
AXSM icon
18
Axsome Therapeutics
AXSM
$11.2B
$32.2M 1.7%
400,000
– –
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$340M
$31.6M 1.66%
1,466,051
– –
FATE icon
20
Fate Therapeutics
FATE
$286M
$26.9M 1.42%
8,215,910
– –
LEGN icon
21
Legend Biotech
LEGN
$3.59B
$26.6M 1.4%
600,000
– –
THRD
22
DELISTED
Third Harmonic Bio
THRD
$26M 1.37%
2,000,000
– –
GERN icon
23
Geron
GERN
$828M
$25.4M 1.34%
6,000,000
– –
RCUS icon
24
Arcus Biosciences
RCUS
$3.55B
$24.4M 1.29%
1,602,200
– –
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.06B
$23.4M 1.23%
600,000
– –
1
2 3

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Boxer Capital held 63 positions worth $1.9B, down 6.2% from $2.02B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Boxer Capital deployed $65.1M of net new capital in Q2 2024, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Climb Bio: 2,603,190 shares worth $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the most notable exit was Viking Therapeutics, an estimated $24.6M sold.

  • Boxer Capital's largest Q2 2024 buy was Climb Bio: 2,603,190 shares worth $18.5M.
  • Boxer Capital added most to iTeos Therapeutics in Q2 2024, an estimated $16.4M increase.
  • Boxer Capital fully exited Viking Therapeutics in Q2 2024, selling an estimated $24.6M.
  • Boxer Capital's ten largest holdings make up 54% of its $1.9B portfolio in Q2 2024.
  • Boxer Capital opened 4 new positions and closed 2 in Q2 2024.
  • Boxer Capital's portfolio value fell 6.2% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q2 2024, filed 14 Aug 2024.